<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4783">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654637</url>
  </required_header>
  <id_info>
    <org_study_id>TCU-CHHuang</org_study_id>
    <nct_id>NCT04654637</nct_id>
  </id_info>
  <brief_title>Multiple Interactive With Nutrition and Exercise Strategies in Frailty Cancer Patients</brief_title>
  <official_title>Department of Nursing, Tzu Chi University, Hualien, Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tzu Chi University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tzu Chi University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to the changes in lifestyle caused by the COVID-19, it is a priority to provide&#xD;
      multi-interactive digital platforms and social media for nutrition and exercise programs for&#xD;
      cancer patients. A two-year serial program uses mixed study methods of longitudinal combined&#xD;
      experimental study. We will investigate cancer frailty's current situation and track the&#xD;
      frailty trends after cancer patients received different treatments. We will also invite&#xD;
      experts to develop multi-interactive digital platforms of nutrition and performance-based&#xD;
      tailored circuit training programs according to the cancer frailty survey. We will recruit&#xD;
      20-85 years of newly diagnosed or first-time recurrence cancer patients and stratified&#xD;
      randomization assigned to evaluate nutrition and physical exercise intervention&#xD;
      effectiveness. The measure indicators were treatment-related adverse events, nutritional&#xD;
      status, frailty status, survival rate, and life quality.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Arm A: fix model of cycle exercise(online supervise) and routine nutrition consult Arm B: fix model of cycle exercise(online supervise) and online nutrition consult Arm C: individualize cycle exercise(online supervise) and routine nutrition consult Arm D: individualize cycle exercise(online supervise) and online nutrition consult</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frailty trend</measure>
    <time_frame>After treatment three-month</time_frame>
    <description>After treatment frailty condition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>After treatment one month</time_frame>
    <description>CTCAE or Clavien-Dindo classification</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Survival</measure>
    <time_frame>The OS was calculated from the date of diagnosis to the date of death or was censored at the date of the last follow-up (3 years from diagnosed) for surviving patients.</time_frame>
    <description>from diagnosed to the dead date</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fix model of cycle exercise(online supervise) and routine nutrition consult</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fix model of cycle exercise(online supervise) and online nutrition consult</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>individualize cycle exercise(online supervise) and routine nutrition consult</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>individualize cycle exercise(online supervise) and online nutrition consult</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nutrition and Exercise Strategies</intervention_name>
    <description>Multiple Interactive with Nutrition and Exercise Strategies</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged from 20-85 years with histological confirmation malignancy.&#xD;
&#xD;
          -  Requiring treatment by surgery, chemotherapy, hormonotherapy, radiotherapy, or&#xD;
             targeted therapy with a curative intention as estimated by oncologists.&#xD;
&#xD;
          -  First diagnosed or recurrence of head and neck cancer, esophageal cancer, colon/rectum&#xD;
             cancer, lung cancer, AML, ALL, lymphoma, multiple myeloma.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-head and neck cancer, esophageal cancer, colon/rectum cancer, lung cancer, AML,&#xD;
             ALL, lymphoma, multiple myeloma with first diagnosis or recurrence patients.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group test score&gt;2.&#xD;
&#xD;
          -  Serious psychiatric or cognitive problems, and functional disability leading to a&#xD;
             total inability to walk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chu Hou Huang, PhD</last_name>
    <phone>886-3-565301</phone>
    <phone_ext>2227</phone_ext>
    <email>hou2017@gms.tcu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tzu Chi University</name>
      <address>
        <city>Hualien City</city>
        <zip>90093</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun Hou Huang, Phd</last_name>
      <phone>886-978650985</phone>
      <email>hou2017@gms.tcu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tzu Chi University</investigator_affiliation>
    <investigator_full_name>Chun Hou Huang</investigator_full_name>
    <investigator_title>Assistance Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

